Affordable Access

[Heparin in the treatment and secondary prevention of myocardial infarction. A critical review of the main trials].

Authors
  • Kher, A
  • Samama, M
  • Haïat, R
Type
Published Article
Journal
Archives des maladies du coeur et des vaisseaux
Publication Date
Nov 01, 1991
Volume
84
Issue
11
Pages
1581–1586
Identifiers
PMID: 1662479
Source
Medline
License
Unknown

Abstract

The aim of this article is to assess the therapeutic value of standard heparin in the acute phase and secondary prevention of myocardial infarction. Only clinical trials with an adequate methodology have been analysed. In patients having undergone thrombolytic therapy associated with aspirin, heparin slightly reduces the mortality but only during the period of its administration. In a metaanalysis of approximately twenty clinical trials of patients not receiving thrombolytic or aspirin therapy, heparin was associated with a significant reduction of deep vein thrombosis, pulmonary embolism, recurrent myocardial infarction and cerebrovascular accidents. In the context of secondary prevention of myocardial infarction, the administration of a moderate dose of subcutaneous heparin resulted in a beneficial effect on morbidity and mortality in one published trial. The use of low molecular weight heparins for the prevention of coronary thrombosis merits attention because of the pharmacological and pharmacokinetic properties of these products.

Report this publication

Statistics

Seen <100 times